EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at the 23rd Annual VIVA Conference in Las Vegas, NV. PROWL national co-principal investigators Dr. Sean Lyden and. ...

Core Insights - Surmodics, Inc. announced a presentation discussing updated safety and performance data from the PROWL registry involving 160 patients with symptomatic lower extremity vessels treated with the Pounce™ Thrombectomy Platform [1] Company Overview - Surmodics, Inc. is a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry [1]